Kapelios CJ, et al. - Researchers evaluated links between high-dose spironolactone and decongestion and safety in patients with acute congestive heart failure (ACHF), given that relief of congestion has prognostic implications in ACHF. Participants were 20 retrospectively examined patients who were hospitalized with ACHF and received high doses of spironolactone (75–300 mg daily, group A) on top of standard of care (SOC) treatment vs 20 matched patients who received SOC treatment alone (group B). According to findings, administration of high doses of spironolactone on top of SOC treatment appeared safe in ACHF patients and was related to greater decongestion compared with SOC alone.